Sleep Breath 2001; 05(1): 023-034
DOI: 10.1055/s-2001-12792
ORIGINAL ARTICLE

Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Treatment of Snoring and Obstructive Sleep Apnea with a Mandibular Protruding Device: An Open-Label Study

Anette M.C. Fransson1 , Göran Isacsson1 , Lena C. Leissner2 , Anders B. Näsman3 , Marianne K. Alton4
  • 1Department of Stomatognathic Physiology, Postgraduate Dental Education Center, Örebro, Sweden
  • 2Sleep Unit, Department of Neurology, , Örebro Medical Center Hospital, Örebro, Sweden
  • 3Department of Otorhinolaryngology and Head and Neck Surgery, Örebro Medical Center Hospital, Örebro, Sweden
  • 4Department of Lung Medicine, Örebro Medical Center Hospital, Örebro, Sweden
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Preview

ABSTRACT

The study objectives were to describe the changes in signs and symptoms of obstructive sleep apnea (OSA) and snoring using a mandibular protruding device (MPD) and to define the group of responders. The design of the study was a nonrandomized, open-labeled, prospective clinical study with a duration of 6 months. The setting was a hospital sleep laboratory and an ear, nose, and throat and dental outpatient clinic. Patients included 35 individuals treated: 22 with a diagnosis of OSA and 13 who snored without apnea.

The intervention before MPD prescription entailed a medical examination, a one-night somnographic registration, a questionnaire, and a clinical jaw function examination. All procedures were iterated at the 6-month follow-up. When the patients used the MPD, the subjective symptoms decreased significantly (p < 0.001). Twenty-four of the 35 patients were classified as responders, i.e., reduced their symptoms ≥50%. In the groups of OSA patients, the mean peak intensity of the snoring sound decreased from 71.6 dB to 62.0 dB (p < 0.001) and in the group of snorers, from 63.5 dB to 57.5 dB (p < 0.05). Eighteen of the 22 OSA patients decreased their ODI values by ≥50% (responders). The mean ODI decreased from 15.4 to 3.5 (p < 0.001) and the blood oxygen saturation, SaO2 nadir, increased from mean 81.9 to 85.7 (n.s.). Most patients with tongue base hyperplasia were classified as responders to the MPD treatment.

In conclusion, a 6-month perspective shows that the MPD could be an effective treatment in reducing signs and symptoms of OSA and/or snoring, the compliance was acceptable and only minor adverse events occurred.

REFERENCES